Intestinal occlusion by gynecological cancers treated by percutaneous endoscopic gastrostomy and lanreotide: an Aviano National Cancer Institute experience

Martina Budel; Luca Martella; Laura Zambon; Isabella Morson; Giorgio Giorda; Renato Cannizzaro

doi:10.1007/s00520-020-05745-x

Intestinal occlusion by gynecological cancers treated by percutaneous endoscopic gastrostomy and lanreotide: an Aviano National Cancer Institute experience

Martina Budel, Luca Martella, Laura Zambon, Isabella Morson, Giorgio Giorda, Renato Cannizzaro

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The Commentary reports on our experience in Centro di Riferimento Oncologico IRCCS Aviano about the integrated and combined treatment with percutaneous endoscopic gastrostomy and lanreotide in patients with bowel obstructions by ovarian cancer and peritoneal carcinomatosis. We treated patients with gynecological cancers and bowel obstruction with percutaneous endoscopic gastrostomy and, when patients were partially responsive, with lanreotide. We registered a constant overall benefit for the quality of life and for the control of symptoms, which is very important especially during the home care follow-up of terminal patients.

Original language	English
Pages (from-to)	547-549
Number of pages	3
Journal	Supportive Care in Cancer
Volume	29
Issue number	2
DOIs	https://doi.org/10.1007/s00520-020-05745-x
Publication status	Published - Feb 2021

Keywords

Gynecological cancers
Lanreotide
Percutaneous endoscopic gastrostomy

ASJC Scopus subject areas

Oncology

Access to Document

10.1007/s00520-020-05745-x

Fingerprint Dive into the research topics of 'Intestinal occlusion by gynecological cancers treated by percutaneous endoscopic gastrostomy and lanreotide: an Aviano National Cancer Institute experience'. Together they form a unique fingerprint.

Cite this

Intestinal occlusion by gynecological cancers treated by percutaneous endoscopic gastrostomy and lanreotide : an Aviano National Cancer Institute experience. / Budel, Martina; Martella, Luca; Zambon, Laura; Morson, Isabella; Giorda, Giorgio ; Cannizzaro, Renato.

In: Supportive Care in Cancer, Vol. 29, No. 2, 02.2021, p. 547-549.

Research output: Contribution to journal › Comment/debate › peer-review

@article{b6a1abee567544bba503ba9bfad774e5,

title = "Intestinal occlusion by gynecological cancers treated by percutaneous endoscopic gastrostomy and lanreotide: an Aviano National Cancer Institute experience",

abstract = "The Commentary reports on our experience in Centro di Riferimento Oncologico IRCCS Aviano about the integrated and combined treatment with percutaneous endoscopic gastrostomy and lanreotide in patients with bowel obstructions by ovarian cancer and peritoneal carcinomatosis. We treated patients with gynecological cancers and bowel obstruction with percutaneous endoscopic gastrostomy and, when patients were partially responsive, with lanreotide. We registered a constant overall benefit for the quality of life and for the control of symptoms, which is very important especially during the home care follow-up of terminal patients.",

keywords = "Gynecological cancers, Lanreotide, Percutaneous endoscopic gastrostomy",

author = "Martina Budel and Luca Martella and Laura Zambon and Isabella Morson and Giorgio Giorda and Renato Cannizzaro",

note = "Funding Information: The project was supported by the Italian Ministry of Health (Ricerca Corrente) [no grant number provided]. Publisher Copyright: {\textcopyright} 2020, The Author(s). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2021",

month = feb,

doi = "10.1007/s00520-020-05745-x",

language = "English",

volume = "29",

pages = "547--549",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Intestinal occlusion by gynecological cancers treated by percutaneous endoscopic gastrostomy and lanreotide

T2 - an Aviano National Cancer Institute experience

AU - Budel, Martina

AU - Martella, Luca

AU - Zambon, Laura

AU - Morson, Isabella

AU - Giorda, Giorgio

AU - Cannizzaro, Renato

N1 - Funding Information: The project was supported by the Italian Ministry of Health (Ricerca Corrente) [no grant number provided]. Publisher Copyright: © 2020, The Author(s). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2021/2

Y1 - 2021/2

N2 - The Commentary reports on our experience in Centro di Riferimento Oncologico IRCCS Aviano about the integrated and combined treatment with percutaneous endoscopic gastrostomy and lanreotide in patients with bowel obstructions by ovarian cancer and peritoneal carcinomatosis. We treated patients with gynecological cancers and bowel obstruction with percutaneous endoscopic gastrostomy and, when patients were partially responsive, with lanreotide. We registered a constant overall benefit for the quality of life and for the control of symptoms, which is very important especially during the home care follow-up of terminal patients.

AB - The Commentary reports on our experience in Centro di Riferimento Oncologico IRCCS Aviano about the integrated and combined treatment with percutaneous endoscopic gastrostomy and lanreotide in patients with bowel obstructions by ovarian cancer and peritoneal carcinomatosis. We treated patients with gynecological cancers and bowel obstruction with percutaneous endoscopic gastrostomy and, when patients were partially responsive, with lanreotide. We registered a constant overall benefit for the quality of life and for the control of symptoms, which is very important especially during the home care follow-up of terminal patients.

KW - Gynecological cancers

KW - Lanreotide

KW - Percutaneous endoscopic gastrostomy

UR - http://www.scopus.com/inward/record.url?scp=85090772839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090772839&partnerID=8YFLogxK

U2 - 10.1007/s00520-020-05745-x

DO - 10.1007/s00520-020-05745-x

M3 - Comment/debate

C2 - 32914327

AN - SCOPUS:85090772839

VL - 29

SP - 547

EP - 549

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 2

ER -